Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01771653 · ClinicalTrials.gov registry record
Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection
A clinical trial, sponsored by Southern Illinois University.
- Completed
- Registry status
- 37
- Enrollment target
NCT01771653: Completed study, sponsored by Southern Illinois University.
NCT01771653 is a clinical trial that has completed, run by Southern Illinois University. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01771653 has completed, sponsored by Southern Illinois University.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
The purpose of this observational study is to compare two approved treatment regimen(s) containing boceprevir and telaprevir, as part of standard of care for the treatment of hepatitis C.
Primary Outcome
Sustained Virologic Response (SVR) rates will be compared between the two arms of treatment through measured HCV RNA levels after 24 weeks, 48 weeks and 96 weeks after completion of treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-07 |
What the finished NCT01771653 record still lists
NCT01771653 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01771653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01771653 about?
NCT01771653 is a clinical study titled "Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection". The purpose of this observational study is to compare two approved treatment regimen(s) containing boceprevir and telaprevir, as part of standard of care for the treatment of hepatitis C.
What is the current status of trial NCT01771653?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2011-09. Estimated completion is 2015-07.
Who is sponsoring clinical trial NCT01771653?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia